Skip to main content
Erschienen in: Infection 4/2014

01.08.2014 | Correspondence

HIV-associated multicentric Castleman’s disease after initiation of antiretroviral therapy: experience of a European centre

verfasst von: J. Katchanov, U. Zimmermann, G. Branding, K. Arastéh, M. Müller

Erschienen in: Infection | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Excerpt

Multicentric Castleman’s disease (MCD) is a non-AIDS-defining lymphoproliferative disorder diagnosed with increased frequency in people infected with HIV [13]. Epidemiological studies have demonstrated no correlation with CD4 cell count or the use of antiretroviral therapy (ART) [1, 2]. However, as early 1999, Zietz and colleagues reported a clustering of MCD cases in HIV-infected patients on highly active ART [4]. In our study, we analysed the temporal relationship between the initiation of ART and the occurrence of HIV-associated MCD (HIV-MCD) in 21 consecutive patients with HIV-MCD in a European HIV referral centre. We defined ART-associated HIV-MCD (in analogy with ART-associated cryptococcosis) as a disease that occurs within 12 months of ART initiation, reintroduction or regimen switching after previous failure [5]. …
Literatur
1.
Zurück zum Zitat Powles T, Stebbing J, Bazeos A, Hatzimichael E, Mandalia S, Nelson M, et al. The role of immune suppression and HHV-8 in the increasing incidence of HIV-associated multicentric Castleman’s disease. Ann Oncol. 2009;20:775–9.PubMedCrossRef Powles T, Stebbing J, Bazeos A, Hatzimichael E, Mandalia S, Nelson M, et al. The role of immune suppression and HHV-8 in the increasing incidence of HIV-associated multicentric Castleman’s disease. Ann Oncol. 2009;20:775–9.PubMedCrossRef
2.
Zurück zum Zitat Bower M. How I treat HIV-associated multicentric Castleman disease. Blood. 2010;116:4415–21.PubMedCrossRef Bower M. How I treat HIV-associated multicentric Castleman disease. Blood. 2010;116:4415–21.PubMedCrossRef
3.
Zurück zum Zitat Hoffmann C, Schmid H, Müller M, Teutsch C, van Lunzen J, Esser S, et al. Improved outcome with rituximab in patients with HIV-associated multicentric Castleman disease. Blood. 2011;118:3499–503.PubMedCrossRef Hoffmann C, Schmid H, Müller M, Teutsch C, van Lunzen J, Esser S, et al. Improved outcome with rituximab in patients with HIV-associated multicentric Castleman disease. Blood. 2011;118:3499–503.PubMedCrossRef
4.
Zurück zum Zitat Zietz C, Bogner JR, Goebel FD, Löhrs U. An unusual cluster of cases of Castleman’s disease during highly active antiretroviral therapy for AIDS. N Engl J Med. 1999;340:1923–4.PubMedCrossRef Zietz C, Bogner JR, Goebel FD, Löhrs U. An unusual cluster of cases of Castleman’s disease during highly active antiretroviral therapy for AIDS. N Engl J Med. 1999;340:1923–4.PubMedCrossRef
5.
Zurück zum Zitat Haddow LJ, Colebunders R, Meintjes G, Lawn SD, Elliott JH, Manabe YC, et al.; International Network for the Study of HIV-associated IRIS (INSHI). Cryptococcal immune reconstitution inflammatory syndrome in HIV-1-infected individuals: proposed clinical case definitions. Lancet Infect Dis. 2010;10:791–802.PubMedCentralPubMedCrossRef Haddow LJ, Colebunders R, Meintjes G, Lawn SD, Elliott JH, Manabe YC, et al.; International Network for the Study of HIV-associated IRIS (INSHI). Cryptococcal immune reconstitution inflammatory syndrome in HIV-1-infected individuals: proposed clinical case definitions. Lancet Infect Dis. 2010;10:791–802.PubMedCentralPubMedCrossRef
6.
Zurück zum Zitat Letang E, Lewis JJ, Bower M, Mosam A, Borok M, Campbell TB, et al. Immune reconstitution inflammatory syndrome associated with Kaposi sarcoma: higher incidence and mortality in Africa than in the UK. AIDS. 2013;27:1603–13.PubMedCrossRef Letang E, Lewis JJ, Bower M, Mosam A, Borok M, Campbell TB, et al. Immune reconstitution inflammatory syndrome associated with Kaposi sarcoma: higher incidence and mortality in Africa than in the UK. AIDS. 2013;27:1603–13.PubMedCrossRef
7.
Zurück zum Zitat Lawn SD, Meintjes G. Pathogenesis and prevention of immune reconstitution disease during antiretroviral therapy. Expert Rev Anti Infect Ther. 2011;9:415–30.PubMedCentralPubMedCrossRef Lawn SD, Meintjes G. Pathogenesis and prevention of immune reconstitution disease during antiretroviral therapy. Expert Rev Anti Infect Ther. 2011;9:415–30.PubMedCentralPubMedCrossRef
8.
Zurück zum Zitat Lee SM, Edwards SG, Chilton DN, Ramsay A, Miller RF. Highly active antiretroviral therapy alone may be an effective treatment for HIV-associated multi-centric Castleman’s disease. Haematologica. 2010;95:1979–81.PubMedCentralPubMedCrossRef Lee SM, Edwards SG, Chilton DN, Ramsay A, Miller RF. Highly active antiretroviral therapy alone may be an effective treatment for HIV-associated multi-centric Castleman’s disease. Haematologica. 2010;95:1979–81.PubMedCentralPubMedCrossRef
Metadaten
Titel
HIV-associated multicentric Castleman’s disease after initiation of antiretroviral therapy: experience of a European centre
verfasst von
J. Katchanov
U. Zimmermann
G. Branding
K. Arastéh
M. Müller
Publikationsdatum
01.08.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
Infection / Ausgabe 4/2014
Print ISSN: 0300-8126
Elektronische ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-014-0605-5

Weitere Artikel der Ausgabe 4/2014

Infection 4/2014 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.